Ivonescimab, a new drug combining the mechanisms of two leading cancer therapies, has shown remarkable efficacy in reducing mortality among patients with squamous non-small cell lung cancer. In a clinical trial conducted solely in China by Akeso Therapeutics, the drug demonstrated a 34% reduction in the risk of death compared to standard treatments. This promising outcome was presented at the annual meeting of the American Society of Clinical Oncology and is also published in The Lancet. Oncologists have expressed optimism regarding these results, which surpass initial expectations. Robert Duggan, co-CEO of Summit Therapeutics, which is developing the drug outside China, emphasized the significance of this data, asserting that it positions the company favorably in the competitive oncology market. The findings are expected to stimulate discussions about the role of China in the global drug development arena and the future of cancer therapies. Akeso Therapeutics did not provide comments regarding the trial results or their implications for future research and development efforts.